New research from Bayes Business School, in collaboration with biopharmaceuticals company Merck KGaA, suggests member states from the European Union (EU) must work more closely together, provide ...

Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in ...

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Summit, a specialist in oncology, has made excellent clinical progress with its leading candidate, ivonescimab. There's more where that came from, too; Ivonescimab just knocked it out of the park in ...

More than 80% of oncologists participating in a global survey consider insurance a major barrier to timely cancer care.

Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics ...

AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced it has signed a binding ...

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.